Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 12, Issue 2, Pages 147-168Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3930
Keywords
-
Funding
- US National Institutes of Health (NIH) [CA91837, AI49453, AI089624, AI100905, AI070535]
- NIH [AI33068, AI48073, CAI64679, AI101403]
- American Heart Association (AHA) [7510081]
Ask authors/readers for more resources
Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional members of the TNF superfamily of structurally related cytokines. Many of these TNF-related cytokines or their cognate receptors are now in preclinical or clinical development as possible targets for modulating inflammatory diseases and cancer as well as other indications. This Review focuses on the biologics that are currently in clinical trials for immune-related diseases and other syndromes, discusses the successes and failures to date as well as the expanding therapeutic potential of modulating the activity of this superfamily of molecules.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available